ClinicalTrials.gg
Not yet recruitingNCT06532409Updated Aug 1, 2024

Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone

An interventional study of Amoxicillin/CA and IV ceftriaxone in Community-acquired Pneumonia, sponsored by RESnTEC, Institute of Research. Not yet recruiting at 1 site in Pakistan. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing amoxicillin in Community-Acquired Pneumonia — 5 open to participants now, 5 under way, 2 of them phase 3. Amoxicillin · Community-Acquired Pneumonia.

Planned enrollment
8th of 12
114 · median 243
Started
2024
with 2 others
No phase
2 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
RESnTEC, Institute of Research

Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, this one is the 8th largest by planned enrollment, is one of 3 that started in 2024, is one of 2 with no phase, and was the 11th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

5 of the 12 studies testing amoxicillin in Community-Acquired Pneumonia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About amoxicillin

Amoxicillin: first FDA approval 1974 (AMOXIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing amoxicillin in Community-Acquired Pneumonia, or all of them as a file.
02

Study summary

The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.

Read the detailed description

The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.

03

Conditions studied

  • Community-acquired Pneumonia
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of both gender
  • Aged from 2 to 5 years
  • With fever >37.5 C (99.5 F)
  • Will be presented with symptoms and signs of uncomplicated community acquired pneumonia

Exclusion criteria

Exclusion Criteria:

  • Children requiring ICU care (having cyanosis SpO2 \< 85% requiring intubation within first day of admission or in state of shock)
  • Children with conditions like congenital heart disease, chronic lung disease, chronic kidney disease, severe malnutrition, asthma, foreign bodies, sickle cell disease, and immunodeficiency
  • Children with underlying anatomical disorders of the lung like pulmonary sequestration, tracheoesophageal fistula or congenital cystic adenoid malformation
  • Children already on antibiotics
  • Presence of any complication of community acquired pneumonia
  • Patients having symptoms of multi-organ involvement/sepsis
  • to Amoxicillin or Ceftriaxone
  • Other co-existing infections like dengue, malaria, or measles
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Oral Amoxicillin

    Patients in this group will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.

    Drug: Amoxicillin/CA

  • Experimental
    IV Ceftriaxone

    Patients in this group will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.

    Drug: IV ceftriaxone

Interventions

  • DrugAmoxicillin/CA

    Drug page: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.

  • DrugCeftriaxoneStudies of CeftriaxoneCeftriaxone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.

06

What researchers measure

Primary outcomes

  1. Free from fever

    Efficacy will be labeled yes where fever symptoms are resolved (temperature = 98.6ºF) within 3 days.

    Time frame: 3 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Data can be shared with other researchers on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Sep 2025, 11 months later.

Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 11 months is below that.

Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartEst.
Oct 1, 2024
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06532409
Lead sponsor
RESnTEC, Institute of Research
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Oct 1, 2024 (estimated)
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Aug 1, 2024

Study contacts

Asim Din, FCPS
Contact
asimdin@yahoo.com
+923360017562

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amoxicillin · Ceftriaxone

Start the discussion